<DOC>
	<DOCNO>NCT00632359</DOCNO>
	<brief_summary>The goal clinical research study learn Revlimid ( lenalidomide ) help reduce level leukemia body . The safety drug also study .</brief_summary>
	<brief_title>Lenalidomide Chronic Lymphocytic Leukemia ( CLL ) Patients With Residual Disease</brief_title>
	<detailed_description>The Study Drug : Lenalidomide design change body 's immune system may also interfere development tiny blood vessel help support tumor growth . Therefore , theory , may decrease prevent growth cancer cell . Study Drug Administration : If find eligible take part study , take lenalidomide mouth every night day 12 month . You swallow lenalidomide capsule whole , water , time day . Do break , chew , open capsule . If miss dose lenalidomide , take soon remember day . If miss dose , make another day . The dose schedule lenalidomide may change , depend side effect may experience . Study Visits : Once week first 4 week , blood ( 1 tablespoon ) drawn routine test . Blood may draw often dose lenalidomide need change experience side effect . After first 4 week , blood ( 1 tablespoon ) drawn routine test every 2 week doctor think dose lenalidomide change . After , blood ( 1 tablespoon ) drawn every 4 week routine test . On Month 4 12 ( +14 day ) , physical exam blood ( 2-3 teaspoon ) draw check status disease . On Month 4 12 ( +14 day ) , every 3 month ( unless study doctor think necessary ) , bone marrow biopsy aspirate check status disease . Length Study : You continue receive study drug 12 month . You continue study visit long disease remain stable . You take study early disease get bad intolerable side effect occur .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>1 . Patients complete chemotherapy 3 month prior start treatment lenalidomide 9 month prior treatment initiation . 2 . Patients CLL/Small Lymphocytic Lymphoma ( SLL ) achieve complete stable partial remission combination chemotherapy . Patients complete remission need documentation residual disease immunophenotyping and/or PCR molecular testing . 3 . Eastern Cooperative Oncology Group ( ECOG ) /World Health Organization ( WHO ) status 02 . 4 . Adequate renal hepatic function ( creatinine equal less 2mg/dL total bilirubin equal less 2 ) . 5 . Females childbearing potential ( FCBP ) . A female childbearing potential sexually mature woman : 1 ) undergone hysterectomy bilateral oophorectomy ; 2 ) naturally postmenopausal least 24 consecutive month ( NOT menses time precede 24 consecutive month ) . 6 . FCBP must negative serum urine pregnancy test sensitivity least 50 mIU/mL within 1014 day prior within 24 hour start lenalidomide must either commit continued abstinence heterosexual intercourse begin TWO acceptable method birth control ; one highly effective one additional effective method AT THE SAME TIME least 28 day start take lenalidomide . 7 . FCBP must also agree ongoing pregnancy test weekly first four week every 28 day therapy discontinuation treatment . 8 . Men must agree use latex condom sexual contact FCBP even successful vasectomy . All patient must counsel minimum every 28 day pregnancy precaution risk fetal exposure . 9 . Age 18 old . 10 . Signed , write IRBapproved informed consent . 1 . Known sensitivity lenalidomide thalidomide 's derivative 2 . Known positivity HIV active hepatitis B C. 3 . Pregnant breast feeding female . Lactating female must agree breast feed take lenalidomide . 4 . History tuberculosis within last five year recent exposure tuberculosis equal le 6 month . 5 . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form . 6 . Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study . 7 . Use experimental drug therapy within 28 day baseline . 8 . Concurrent use anticancer agent treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>CLL</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>Revlimid</keyword>
</DOC>